tm
Seeing Is Believing
tm
Seeing Is Believing
Currently, out of the existing stock ratings of Chad Mabry - 32 which are a Buy (96.97%), 1 which are a Hold (3.03%)
Analyst Chad Mabry works at B. RILEY and is covering Energy, Healthcare sectors with 66 price targets and ratings displayed on 9 stocks. Previously, Chad Mabry worked at MLV.
Chad Mabry's average stock forecast success ratio is 42.59% with an average time for price targets to be met of 383.56 days.
Most recent stock forecast was given on ALT, Altimmune at 07-Sep-2021.
Analyst best performing recommendations are on QEP.
The best stock recommendation documented was for QEP at 7/21/2016. The price target of $19 was fulfilled within 25 days with a profit of $2.06 (12.16%) receiving and performance score of 4.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
44
$12.8 (41.03%)
53
5 days ago
0/8 (0%)
$46.42 (68.86%)
Buy
42
$10.8 (34.62%)
50
13 days ago
2/11 (18.18%)
$15.79 (43.90%)
29
Buy
63
$31.8 (101.92%)
59
2 months 17 days ago
1/6 (16.67%)
$20.59 (53.42%)
7
Hold
45
$13.8 (44.23%)
40
3 months 19 days ago
4/5 (80%)
$4.68 (13.12%)
63
Buy
48
$16.8 (53.85%)
55
3 months 28 days ago
8/16 (50%)
$11 (39.23%)
39
What Year was the first public recommendation made by Chad Mabry?
